Terrorist Attacks Have No Impact on DIA EuroMeeting
The EuroMeeting and Clinical Forum will take place in Paris as planned, in spite of January’s terrorist attacks in the French capital.
The EuroMeeting and Clinical Forum will take place in Paris as planned, in spite of January’s terrorist attacks in the French capital, according to the Drug Information Association (DIA).
“We are working closely with the venue and the city of Paris to make sure all security measures are taken and onsite security will be reinforced,” noted Natacha Scholl, Team Leader of Operations for DIA in Europe, Middle East & Africa. “We will put everything in place to reassure participants of course.”
She does not anticipate that the attacks will have any great impact on delegate numbers. “Registrations haven't stopped over the past days, despite the tragic events,” she remarked.
As of January 15, there were already more than 650 registered participants, and Scholl said the organizers are expecting at least 2500 to 3000 attendees in total for the two events.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Optimizing Phase III Oncology Trial Recruitment with Data-Driven Insights
February 3rd 2025A pharmaceutical company aimed to launch a Phase III clinical trial for a new oncology drug, focusing on efficient and effective patient recruitment across diverse regions. They evaluated patient populations by analyzing demographics, social determinants of health, and geography. Investigator profiling included practice details, affiliations, referral networks, and clinical trial experience. The final step involved selecting and extracting target lists for implementation.
